This year alone, Certara is delivering 40+ disease specific assessments for US Market success. Would your program benefit from these key deliverables?
- Leverage our wide in-house therapeutic expertise to pressure-test registration, reimbursement, and commercialization assumptions.
- Achieve rapid turnaround for tight due diligence timelines.
- Validate your deal structures with our quantitative net revenue forecasting, adjusting for critical pricing and access scenarios across key payer types.
Are you seeking proven expertise on the shifting pricing and reimbursement environment in the US?
Contact us today for a commercial assessment for new opportunities or pipeline assets, no-charge to Bio-Europe attendees!
Contact a Certara Biotech expert Today: